Shots:

• Lupin’s subsidiary Nanomi to sell its entire stake (99.82%) in Kyowa to Unison’s entity Plutus in an all-cash transaction for an enterprise value of ~$525.87M and will generate post-tax net cash inflow of ~$300M.  The transfer is expected to be completed in Mar’2020
• The divestiture will strengthen Lupin’s balance sheet and its growth capital to support organic and inorganic initiatives- allowing it to focus on key markets
• Kyowa in collaboration with Unison will provide various solutions beyond the pharmaceutical business by leveraging its strong position in CNS generics- longlisted and specialty products with Unison’s investments in healthcare- forming a leading CNS company

Click here- Click here to­ read full press release/ article | Ref: Lupin- Kyowa | Image: Business Standard